2 news items
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome)
CORT
28 May 24
their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
CORT
8 Apr 24
their clinical attributes, regulatory approvals, mandates, oversight and other requirements; and the scope and protective power of our intellectual property
- Prev
- 1
- Next